Kimberley S Samkoe1,2, Jason R Gunn3, Kayla Marra3, Sally M Hull3, Karen L Moodie4, Joachim Feldwisch5, Theresa V Strong6, Daniel R Draney7, P Jack Hoopes8,3,4, David W Roberts8,3, Keith Paulsen8,3, Brian W Pogue9,10. 1. Department of Surgery, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, 03755, USA. kimberley.s.samkoe@dartmouth.edu. 2. Thayer School of Engineering, Dartmouth College, Hanover, NH, 03755, USA. kimberley.s.samkoe@dartmouth.edu. 3. Thayer School of Engineering, Dartmouth College, Hanover, NH, 03755, USA. 4. Center for Comparative Medicine and Research, Dartmouth College, Hanover, NH, 03755, USA. 5. Affibody AB, 171 69, Solna, Sweden. 6. Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL, 35294, USA. 7. LI-COR Biosciences, Lincoln, NB, 68504, USA. 8. Department of Surgery, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, 03755, USA. 9. Department of Surgery, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, 03755, USA. brian.w.pogue@dartmouth.edu. 10. Thayer School of Engineering, Dartmouth College, Hanover, NH, 03755, USA. brian.w.pogue@dartmouth.edu.
Abstract
PURPOSE: ABY-029, a synthetic Affibody peptide, Z03115-Cys, labeled with a near-infrared fluorophore, IRDye® 800CW, targeting epidermal growth factor receptor (EGFR) has been produced under good manufacturing practices for a US Food and Drug Administration-approved first-in-use human study during surgical resection of glioma, as well as other tumors. Here, the pharmacology, phototoxicity, receptor activity, and biodistribution studies of ABY-029 were completed in rats, prior to the intended human use. PROCEDURES: Male and female Sprague Dawley rats were administered a single intravenous dose of varying concentrations (0, 245, 2449, and 24,490 μg/kg corresponding to 10×, 100×, and 1000× an equivalent human microdose level) of ABY-029 and observed for up to 14 days. Histopathological assessment of organs and tissues, clinical chemistry, and hematology were performed. In addition, pharmacokinetic clearance and biodistribution of ABY-029 were studied in subgroups of the animals. Phototoxicity and ABY-029 binding to human and rat EGFR were assessed in cell culture and on immobilized receptors, respectively. RESULTS: Histopathological assessment and hematological and clinical chemistry analysis demonstrated that single-dose ABY-029 produced no pathological evidence of toxicity at any dose level. No phototoxicity was observed in EGFR-positive and EGFR-negative glioma cell lines. Binding strength and pharmacokinetics of the anti-EGFR Affibody molecules were retained after labeling with the dye. CONCLUSION: Based on the successful safety profile of ABY-029, the 1000× human microdose 24.5 mg/kg was identified as the no observed adverse effect level following intravenous administration. Conserved binding strength and no observed light toxicity also demonstrated ABY-029 safety for human use.
PURPOSE: ABY-029, a synthetic Affibody peptide, Z03115-Cys, labeled with a near-infrared fluorophore, IRDye® 800CW, targeting epidermal growth factor receptor (EGFR) has been produced under good manufacturing practices for a US Food and Drug Administration-approved first-in-use human study during surgical resection of glioma, as well as other tumors. Here, the pharmacology, phototoxicity, receptor activity, and biodistribution studies of ABY-029 were completed in rats, prior to the intended human use. PROCEDURES: Male and female Sprague Dawley rats were administered a single intravenous dose of varying concentrations (0, 245, 2449, and 24,490 μg/kg corresponding to 10×, 100×, and 1000× an equivalent human microdose level) of ABY-029 and observed for up to 14 days. Histopathological assessment of organs and tissues, clinical chemistry, and hematology were performed. In addition, pharmacokinetic clearance and biodistribution of ABY-029 were studied in subgroups of the animals. Phototoxicity and ABY-029 binding to human and ratEGFR were assessed in cell culture and on immobilized receptors, respectively. RESULTS: Histopathological assessment and hematological and clinical chemistry analysis demonstrated that single-dose ABY-029 produced no pathological evidence of toxicity at any dose level. No phototoxicity was observed in EGFR-positive and EGFR-negative glioma cell lines. Binding strength and pharmacokinetics of the anti-EGFR Affibody molecules were retained after labeling with the dye. CONCLUSION: Based on the successful safety profile of ABY-029, the 1000× human microdose 24.5 mg/kg was identified as the no observed adverse effect level following intravenous administration. Conserved binding strength and no observed light toxicity also demonstrated ABY-029 safety for human use.
Authors: Richard P Baum; Vikas Prasad; Dirk Müller; Christiane Schuchardt; Anna Orlova; Anders Wennborg; Vladimir Tolmachev; Joachim Feldwisch Journal: J Nucl Med Date: 2010-05-19 Impact factor: 10.057
Authors: Vladimir Tolmachev; Anna Orlova; Fredrik Y Nilsson; Joachim Feldwisch; Anders Wennborg; Lars Abrahmsén Journal: Expert Opin Biol Ther Date: 2007-04 Impact factor: 4.388
Authors: U Schmidt-Erfurth; J W Miller; M Sickenberg; H Laqua; I Barbazetto; E S Gragoudas; L Zografos; B Piguet; C J Pournaras; G Donati; A M Lane; R Birngruber; H van den Berg; H A Strong; U Manjuris; T Gray; M Fsadni; N M Bressler Journal: Arch Ophthalmol Date: 1999-09
Authors: J W Miller; U Schmidt-Erfurth; M Sickenberg; C J Pournaras; H Laqua; I Barbazetto; L Zografos; B Piguet; G Donati; A M Lane; R Birngruber; H van den Berg; A Strong; U Manjuris; T Gray; M Fsadni; N M Bressler; E S Gragoudas Journal: Arch Ophthalmol Date: 1999-09
Authors: Ana Luiza Ribeiro de Souza; Kayla Marra; Jason Gunn; Kimberley S Samkoe; P Jack Hoopes; Joachim Feldwisch; Keith D Paulsen; Brian W Pogue Journal: Mol Imaging Biol Date: 2017-02 Impact factor: 3.488
Authors: Margaret Folaron; Rendall Strawbridge; Kimberley S Samkoe; Caroline Filan; David W Roberts; Scott C Davis Journal: J Neurosurg Date: 2018-09-07 Impact factor: 5.115
Authors: Kimberley S Samkoe; Brent D Bates; Niki N Tselepidakis; Alisha V DSouza; Jason R Gunn; Dipak B Ramkumar; Keith D Paulsen; Brian W Pogue; Eric R Henderson Journal: J Biomed Opt Date: 2017-12 Impact factor: 3.170
Authors: Ana Luiza Ribeiro de Souza; Kayla Marra; Jason Gunn; Kimberley S Samkoe; Sally Hull; Keith D Paulsen; Brian W Pogue Journal: Photochem Photobiol Date: 2018-09-28 Impact factor: 3.421